OXGN
Seguramente. De todas formas, el lograr un combo sin quimio que funciona lo veo como algo muy positivo y, lo que decíamos el otro día, garantiza que se siga estudiando. Los otros objetivos secundarios se han cumplido. Es una buena inversión a largo diría yo, y puede que aprovechen para sacudir el árbol.
«Después de nada, o después de todo/ supe que todo no era más que nada.»
INO
Inovio Pharmaceuticals (NASDAQ:INO): Q3 EPS of -$0.12 beats by $0.02.
Revenue of $1.8M (-81.0% Y/Y) misses by $3.78M.
«Después de nada, o después de todo/ supe que todo no era más que nada.»
ACTC
Artículo ultrabullish de ACTC en SA. Lástima que saliera el viernes por la noche en lugar de hoy en mitad de la sesión. Otorga un precio de 4500$/acción. Ya molaría y bueno, quizá en 10 años si todo va bien, pero me parece poco realista.
http://seekingalpha.com/article/2658165-advanced-cell-technology-is-severely-undervalued?uprof=45
«Después de nada, o después de todo/ supe que todo no era más que nada.»
ONVO
Leyendo el informe dicen que tienen pasta para 12 meses.
Comecialización a finales de este mes.
El consejero general compra 150000 acciones (stock options) a 6,84.
Organovo (NYSE: ONVO) reported Q2 EPS of ($0.11), versus ($0.14) reported last year. Revenue for the quarter came in at $50 thousand, versus $23 thousand reported last year (+150.0% Y/Y).
we are ready to initiate the commercialization of our 3D Liver Tissue before the end of November, 2014
For the six months ended September 30, 2014, total revenues of $0.1 million were consistent with the $0.1 million in revenues for the same period in 2013. For all periods, the majority of revenues were derived from collaborative research agreements.
expenses increased approximately $3.4 million, or 61%. $1.8 million relates to increased selling, general and . administrative expense while the other $1.6 million relates to increased investment in research and development. Research and development expenses increased nearly 100% from approximately $1.6 million for the three months ended September 30, 2013 to $3.2 million for the three months ended September 30, 2014, as the Company grew its research staff to support its obligations under certain collaborative research agreements and to expand its product development efforts in preparation for research-derived revenues. Full-time research and development staffing increased from twenty-four full-time employees as of September 30, 2013 to forty-four full-time employees as of September 30, 2014.
Other income was less than $0.1 million for the three months ended September 30, 2014 and consisted primarily of a gain related to the revaluation of warrant derivative liabilities. This gain was caused by a declining stock price during the quarter that decreased the value of the derivative liability.
During September of 2014, the NIH awarded the Company a research grant totaling approximately $222,000. The grant provides for fixedpayments based on the achievement of certain milestones. As such, revenue will be recognized upon completion of those milestones. Grant activities did not commence until the third quarter of fiscal 2015 and therefore no revenue has been recognized under this grant as of September 30, 2014.
In October 2014, we executed an amendment to our existing Research Agreement with United Therapeutics Corporation (“Unither”) to expand the scope of research we are conducting using the NovoGen Bioprinter technology. The term of our extended Research Agreement with Unither now runs through December 2015.
No leo ni una palabra sobre sus acuerdos con L'Oreal, Pfizer, Roche...
«Después de nada, o después de todo/ supe que todo no era más que nada.»
OXGN
Menuda locura el pre de OXGN. No tiene ningún sentido.
«Después de nada, o después de todo/ supe que todo no era más que nada.»
OFF-TOPIC
PT vendidas en pre de 2,58 a 2,67. Me quedo con el precio que ofrecen en la opa de hoy porque hoy no espero que suba de ahí. Si baja, volveré a meterle a la espera de la próxima oferta.
«Después de nada, o después de todo/ supe que todo no era más que nada.»
OXGN
Aquí está.
Aside from lack of OS benefit/, my biggest fosbretabulin question: Why would drug work better in plat-refractory vs sensitive?
«Después de nada, o después de todo/ supe que todo no era más que nada.»
NVAX.
Novavax Initiates Phase 1 Clinical Trial of RSV F Vaccine in Pediatric Subjects
GAITHERSBURG, Md., Nov. 10, 2014 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that enrollment has begun in a Phase 1 clinical trial of its respiratory syncytial virus (RSV) F-protein nanoparticle vaccine candidate (RSV F Vaccine), in healthy children, the first study of this vaccine candidate to be conducted in a pediatric population.
The trial, which is being conducted in Canada, is a randomized, observer-blinded, dose-ranging Phase 1 study to evaluate the safety and immunogenicity of the RSV F Vaccine, with or without aluminum phosphate adjuvant, in 150 healthy pediatric subjects two to six years of age. In addition to the trial’s primary goal of evaluating safety in this population, the study will also evaluate immunogenicity as measured by concentrations of serum IgG antibodies to the RSV fusion, or F-protein, palivizumab-competing antibody titers and RSV microneutralization titers.
